Literature DB >> 2107279

The modern management of Parkinson's disease.

N Quinn1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2107279      PMCID： PMC487942          DOI： 10.1136/jnnp.53.2.93

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  26 in total

1.  Apomorphine in Parkinson's disease.

Authors:  R S SCHWAB; L V AMADOR; J Y LETTVIN
Journal:  Trans Am Neurol Assoc       Date:  1951

2.  Human brain monoamine oxidase: multiple forms and selective inhibitors.

Authors:  M B Youdim; G G Collins; M Sandler; A B Bevan Jones; C M Pare; W J Nicholson
Journal:  Nature       Date:  1972-03-31       Impact factor: 49.962

3.  Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

Authors:  T P Singer; N Castagnoli; R R Ramsay; A J Trevor
Journal:  J Neurochem       Date:  1987-07       Impact factor: 5.372

4.  Lipid peroxidation as cause of nigral cell death in Parkinson's disease.

Authors:  D Dexter; C Carter; F Agid; Y Agid; A J Lees; P Jenner; C D Marsden
Journal:  Lancet       Date:  1986-09-13       Impact factor: 79.321

5.  L-Dopa methyl ester--a candidate for chronic systemic delivery of L-Dopa in Parkinson's disease.

Authors:  D R Cooper; C Marrel; B Testa; H van de Waterbeemd; N Quinn; P Jenner; C D Marsden
Journal:  Clin Neuropharmacol       Date:  1984       Impact factor: 1.592

6.  On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study.

Authors:  R J Hardie; A J Lees; G M Stern
Journal:  Brain       Date:  1984-06       Impact factor: 13.501

7.  Therapeutic efficacy of apomorphine combined with an extracerebral inhibitor of dopamine receptors in Parkinson's disease.

Authors:  G U Corsini; M Del Zompo; G L Gessa; A Mangoni
Journal:  Lancet       Date:  1979-05-05       Impact factor: 79.321

8.  Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors.

Authors:  R E Heikkila; L Manzino; F S Cabbat; R C Duvoisin
Journal:  Nature       Date:  1984 Oct 4-10       Impact factor: 49.962

9.  Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up.

Authors:  U K Rinne
Journal:  Neurology       Date:  1987-05       Impact factor: 9.910

10.  Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study.

Authors:  W Birkmayer; J Knoll; P Riederer; M B Youdim; V Hars; J Marton
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575
View more
  2 in total

1.  Buspirone in the treatment of levodopa induced dyskinesias.

Authors:  B Kleedorfer; A J Lees; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-04       Impact factor: 10.154

Review 2.  Selegiline: an appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in Parkinson's disease.

Authors:  H M Bryson; R J Milne; P Chrisp
Journal:  Pharmacoeconomics       Date:  1992-08       Impact factor: 4.981
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.